Adriamycin can be used with relative safety and high efficacy in a dosage schedule that resulted from pharmacologic studies. Dosage reduction in patients with liver disease is essential to avoid life-threatening
2:45 Accelerated Bioinformatics - The Promises and Pitfalls Martin Gollery, CEO and Chief Consultant, Tahoe Informatics Server farms to feed the ever-growing need for Biocomputing processing power have become huge drains on electricity, Air Conditioning, floorspace and manpower. To reduce these ...
Since this epigenetic change is reversible, it is a potential target for chemotherapeutic intervention using an inhibitor of DNA methylation, such as 5-aza-2'-deoxycytidine (DAC). Although clinical studies show that DAC has activity against hematological malignancies, the optimal dose-schedule of ...
Dose reductions occurred in 30 % of patients, 12 % for neutropenia and 16 % for neuropathy. The most common grade 3/4 toxicity was neutropenia (16 %), and 25 % of patients had no residual cancer cells or only microscopic residual disease burden (residual cancer burden 0 or 1 by Symann...
Other studies have evaluated the combination of FU with l-OHP and/or IRI administered as chronomodulated infusion. These trials also reported interesting response rates and optimal toxicity profiles, but raised questions about the feasibility of chronomodulated chemotherapy (Garufi et al, 2003). ...
The immunogenicity results of the current study are also comparable with those of the phase 3 studies in adolescents and young adults who were administered a 3-dose MenB-FHbp schedule (at 0, 2, and 6 months) [19]. The lower limit of the 2-sided 95% CI (57.8%) for PMB80 (A22)...
Since this epigenetic change is reversible, it is a potential target for chemotherapeutic intervention using an inhibitor of DNA methylation, such as 5-aza-2'-deoxycytidine (DAC). Although clinical studies show that DAC has activity against hematological malignancies, the optimal dose-schedule of ...
(4) Conclusions: The “sandwich” schedule for CT and RT combination is an effective adjuvant treatment with low toxicity both in intermediate–high- and high-risk EC. Keywords: endometrial cancer; chemotherapy; radiotherapy; sandwich schedule; toxicity...